Published in:
Open Access
01-02-2013 | Original Paper
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice
Authors:
Domenico Angelucci, Nicola Tinari, Antonino Grassadonia, Ettore Cianchetti, Giampiero Ausili-Cefaro, Laura Iezzi, Marinella Zilli, Simona Grossi, Lucia Anna Ursini, Maria Teresa Scognamiglio, Graziella Castrilli, Michele De Tursi, Paolo Noccioli, Pasquale Cioffi, Stefano Iacobelli, Clara Natoli
Published in:
Journal of Cancer Research and Clinical Oncology
|
Issue 2/2013
Login to get access
Abstract
Purpose
The aim of this study is to evaluate the long-term outcome of patients with locally advanced breast cancer treated with neoadjuvant systemic chemotherapy (NST) in routine clinical practice.
Methods
Four hundred and nine patients were identified between January 1999 and December 2011. All patients received NST followed by surgery, adjuvant treatments and radiotherapy, as appropriate.
Results
At Kaplan–Meier analysis, patients with surgical stage III disease were more likely to develop distant metastasis and die from breast cancer (p < 0.001). Luminal A and luminal B/HER2-negative patients had better prognosis; moreover, patients with hormone receptor (HR)-positive tumors had a significantly longer DRFS (p < 0.0049) and OS (p < 0.0001) compared with patients with HR-negative tumors as well as patients who underwent breast-conserving surgery (DRFS and OS: p < 0.001). In multivariate analysis, HR negativity (p < 0.001 for both DRFS and OS), mastectomy (DRFS: p = 0.009; OS: p = 0.05) and stage III disease (DRFS: p < 0.001; OS: p = 0.003) were associated with shorter DRFS and OS.
Conclusions
HR negativity, mastectomy and pathological stage III disease are the variables independently associated with a worse outcome in our cohort of patients. These data are of high interest since they derive from a very heterogeneous group of patients, treated with different neoadjuvant/adjuvant regimens outside of clinical trials and with a long follow-up period.